After five years of unprecedented momentum, the ADC field now finds itself at an interesting inflection point. With more programs in development and greater industry prioritization than ever before, ...

You may have noticed an officer standing just behind the President of India at official events, state visits, or ceremonial functions. That officer holds a very important role as an Aide-de-Camp (ADC) ...

With the 2027 general elections fast approaching, the coalition party, African Democratic Congress, is battling internal uncertainty as the anticipated membership of former Vice President Atiku ...

ABUJA – In a bold move to reposition itself as a credible opposition platform, the African Democratic Congress (ADC) has approved the appointment of several prominent political figures, including ...

The pharmaceutical industry says a popular class of targeted cancer therapies could one day replace chemotherapy and its potential for harsh side effects. There is still more work to be done to refine ...

Lieutenant Commander Yashasvi Solanki, 27, has made history as the first female Aide-de-Camp (ADC) to the President of India, Droupadi Murmu. She officially took over the role on May 9, 2025, after a ...

Antibody-drug conjugates (ADCs) are a growing class of biotherapeutics that have transformed targeted therapy, especially in oncology. By making use of monoclonal antibodies’ specificity to deliver ...

The antibody-drug conjugate (ADC) manufacturing landscape offers the potential to leverage significant opportunities for cancer treatment, but faces complex challenges. Nevertheless, the ADC market ...

Merck & Co. has shown off data on its ROR1-directed antibody-drug conjugate (ADC), trumpeting a 100% complete response rate but also reporting safety signals that informed the decision to take the low ...

ADC Therapeutics has stopped development of lead solid tumor candidate ADCT-601. The biotech axed the AXL-directed antibody-drug conjugate (ADC) after failing to show a favorable benefit-risk profile ...

Danish biotech Adcendo has accelerated its progression to a clinical-stage biotech by licensing an antibody-drug conjugate (ADC) from China's Multitude Therapeutics with potential in various forms of ...

Despite some positive trials with new drugs (including immunotherapy) for recurrent cervical cancer, the prognosis for this disease remains poor and additional treatment options are needed. Tisotumab ...